PURPOSE: Animal studies have shown the potential benefits of mannitol as renoprotective during warm ischemia; it may have antioxidant and anti-inflammatory properties and is sometimes used during partial nephrectomy (PN) and live donor nephrectomy (LDN). Despite this, a prospective study on mannitol has never been performed. The aim of this study is to document patterns of mannitol use during PN and LDN. MATERIALS AND METHODS: A survey on the use of mannitol during PN and LDN was sent to 92 high surgical volume urological centers. Questions included use of mannitol, indications for use, physician responsible for administration, dosage, timing and other renoprotective measures. RESULTS: Mannitol was used in 78 and 64 % of centers performing PN and LDN, respectively. The indication for use was as antioxidant (21 %), as diuretic (5 %) and as a combination of the two (74 %). For PN, the most common dosages were 12.5 g (30 %) and 25 g (49 %). For LDN, the most common doses were 12.5 g (36.3 %) and 25 g (63.7 %). Overall, 83 % of centers utilized mannitol, and two (percent or centers??) utilized furosemide for renoprotection. CONCLUSIONS: A large majority of high-volume centers performing PN and LDN use mannitol for renoprotection. Since there are no data proving its value nor standardized indication and usage, this survey may provide information for a randomized prospective study.
PURPOSE: Animal studies have shown the potential benefits of mannitol as renoprotective during warm ischemia; it may have antioxidant and anti-inflammatory properties and is sometimes used during partial nephrectomy (PN) and live donor nephrectomy (LDN). Despite this, a prospective study on mannitol has never been performed. The aim of this study is to document patterns of mannitol use during PN and LDN. MATERIALS AND METHODS: A survey on the use of mannitol during PN and LDN was sent to 92 high surgical volume urological centers. Questions included use of mannitol, indications for use, physician responsible for administration, dosage, timing and other renoprotective measures. RESULTS:Mannitol was used in 78 and 64 % of centers performing PN and LDN, respectively. The indication for use was as antioxidant (21 %), as diuretic (5 %) and as a combination of the two (74 %). For PN, the most common dosages were 12.5 g (30 %) and 25 g (49 %). For LDN, the most common doses were 12.5 g (36.3 %) and 25 g (63.7 %). Overall, 83 % of centers utilized mannitol, and two (percent or centers??) utilized furosemide for renoprotection. CONCLUSIONS: A large majority of high-volume centers performing PN and LDN use mannitol for renoprotection. Since there are no data proving its value nor standardized indication and usage, this survey may provide information for a randomized prospective study.
Authors: Sriram Sampath; John L Moran; Petra L Graham; Sue Rockliff; Andrew D Bersten; Keith R Abrams Journal: Crit Care Med Date: 2007-11 Impact factor: 7.598
Authors: L Badet; P Petruzzo; N Lefrançois; B McGregor; M Espa; C Berthillot; F Danjou; P Contu; A H Aissa; S R Virieux; J J Colpart; X Martin Journal: Transplant Proc Date: 2005 Jan-Feb Impact factor: 1.066
Authors: Massimiliano Spaliviero; Nicholas E Power; Katie S Murray; Daniel D Sjoberg; Nicole E Benfante; Melanie L Bernstein; James Wren; Paul Russo; Jonathan A Coleman Journal: Eur Urol Date: 2017-08-16 Impact factor: 20.096
Authors: José A Damasceno-Ferreira; Leonardo A S Abreu; Gustavo R Bechara; Waldemar S Costa; Marco A Pereira-Sampaio; Francisco J B Sampaio; Diogo B De Souza Journal: BMC Urol Date: 2018-03-06 Impact factor: 2.264
Authors: Christian Reiterer; Karin Hu; Samir Sljivic; Markus Falkner von Sonnenburg; Edith Fleischmann; Alexander Kainz; Barbara Kabon Journal: BMC Nephrol Date: 2020-07-28 Impact factor: 2.388